Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/27742657http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/27742657http://www.w3.org/2000/01/rdf-schema#comment"

Background

Inflammatory myofibroblastic tumors (IMTs) are rare sarcomas that can occur at any age. Surgical resection is the primary treatment for patients with localized disease; however, these tumors frequently recur. Less commonly, patients with IMTs develop or present with metastatic disease. There is no standard of care for these patients and traditional cytotoxic therapy is largely ineffective. Most IMTs are associated with oncogenic ALK, ROS1 or PDGFRβ fusions and may benefit from targeted therapy.

Patient and methods

We sought to understand the genomic abnormalities of a patient who presented for management of metastatic IMT after progression of disease on crizotinib and a significant and durable partial response to the more potent ALK inhibitor ceritinib.

Results

The residual IMT was resected based on the recommendations of a multidisciplinary tumor sarcoma tumor board and analyzed by whole-genome mate pair sequencing. Analysis of the residual, resected tumor identified a chromoplectic TPM3-ALK rearrangement that involved many other known oncogenes and was confirmed by rtPCR.

Conclusions

In our analysis of the treatment-resistant, residual IMT, we identified a complex pattern of genetic rearrangements consistent with chromoplexy. Although it is difficult to know for certain if these chromoplectic rearrangements preceded treatment, their presence suggests that chromoplexy has a role in the oncogenesis of IMTs. Furthermore, this patient's remarkable response suggests that ceritinib should be considered as an option after progression on crizotinib for patients with metastatic or unresectable IMT and ALK mutations."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.org/dc/terms/identifier"doi:10.1093/annonc/mdw405"xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Vasmatzis G."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Jen J."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Wigle D."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Murphy S.J."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Johnson S.H."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Yi E.S."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Marks R.S."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Mansfield A.S."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Harris F.R."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Halling G.C."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Robinson S.I."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/author"Smadbeck J.B."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/date"2016"xsd:gYear
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/name"Ann Oncol"xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/pages"2111-2117"xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/title"Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib."xsd:string
http://purl.uniprot.org/citations/27742657http://purl.uniprot.org/core/volume"27"xsd:string
http://purl.uniprot.org/citations/27742657http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/27742657
http://purl.uniprot.org/citations/27742657http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/27742657
http://purl.uniprot.org/uniprot/#_A0A087WWU8-mappedCitation-27742657http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27742657
http://purl.uniprot.org/uniprot/#_A0A0K2YUJ3-mappedCitation-27742657http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27742657
http://purl.uniprot.org/uniprot/#_D1MAM4-mappedCitation-27742657http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/27742657
▶